Profile of minocycline and its potential in the treatment of schizophrenia

References

• MonjiAKatoTKanbaSCytokines and schizophrenia: microglia hypothesis of schizophreniaPsychiatry Clin Neurosci200963325726519579286
   PubMed Web of Science ®Google Scholar
• KaneJMCorrellCUPast and present progress in the pharmacologic treatment of schizophreniaJ Clin Psychiatry20107191115112420923620
   PubMed Web of Science ®Google Scholar
• LeuchtSArbterDEngelRRKisslingWDavisJMHow effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trialsMol Psychiatry200914442944718180760
   PubMed Web of Science ®Google Scholar
• EssaliAAl HajHNLiCRathboneJClozapine versus typical neuroleptic medication for schizophreniaCochrane Database Syst Rev20091CD00005919160174
   PubMed Web of Science ®Google Scholar
• AsenjoLCKomossaKRummel-KlugeCClozapine versus other atypical antipsychotics for schizophreniaCochrane Database Syst Rev201011CD00663321069690
   PubMedGoogle Scholar
• GilmourGDixSFelliniLNMDA receptors, cognition and schizophrenia – testing the validity of the NMDA receptor hypofunction hypothesisNeuropharmacology20126231401141221420987
   PubMed Web of Science ®Google Scholar
• TerryAVJrRole of the central cholinergic system in the therapeutics of schizophreniaCurr Neuropharmacol20086328629219506725
   PubMed Web of Science ®Google Scholar
• SanderKKottkeTStarkHHistamine H3 receptor antagonists go to clinicsBiol Pharm Bull200831122163218119043195
   PubMed Web of Science ®Google Scholar
• MeltzerHYSerotonergic mechanisms as targets for existing and novel antipsychoticsHandb Exp Pharmacol20122128712423129329
   PubMedGoogle Scholar
• GinovartNKapurSRole of dopamine D(2) receptors for antipsychotic activityHandb Exp Pharmacol2012212275223129327
   PubMedGoogle Scholar
• MulleJGSchizophrenia genetics: progress, at lastCurr Opin Genet Dev201222323824422424801
   PubMed Web of Science ®Google Scholar
• GuptaSKulharaPWhat is schizophrenia: a neurodevelopmental or neurodegenerative disorder or a combination of both? A critical analysisIndian J Psychiatry2010521212720174514
   PubMedGoogle Scholar
• RapoportJLGieddJNGogtayNNeurodevelopmental model of schizophrenia: update 2012Mol Psychiatry201217121228123822488257
   PubMed Web of Science ®Google Scholar
• DeanBUnderstanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studiesInt J Neuropsychopharmacol2011147997101221156092
   PubMed Web of Science ®Google Scholar
• MeyerUAnti-inflammatory signaling in schizophreniaBrain Behav Immun20112581507151821664451
   PubMed Web of Science ®Google Scholar
• MonjiAKatoTAMizoguchiYNeuroinflammation in schizophrenia especially focused on the role of microgliaProg Neuropsychopharmacol Biol Psychiatry201342511512122192886
   PubMed Web of Science ®Google Scholar
• YongVWWellsJGiulianiFCashaSPowerCMetzLMThe promise of minocycline in neurologyLancet Neurol200431274475115556807
   PubMed Web of Science ®Google Scholar
• KimHSSuhYHMinocycline and neurodegenerative diseasesBehav Brain Res2009196216817918977395
   PubMed Web of Science ®Google Scholar
• DeanOMData-FrancoJGiorlandoFBerkMMinocycline: therapeutic potential in psychiatryCNS Drugs201226539140122486246
   PubMed Web of Science ®Google Scholar
• KellerWRKumLMWehringHJKoolaMMBuchananRWKellyDLA review of anti-inflammatory agents for symptoms of schizophreniaJ Psychopharmacol201327433734223151612
   PubMed Web of Science ®Google Scholar
• LevkovitzYLeviUBrawYCohenHMinocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophreniaBrain Res2007115415416217488642
   PubMed Web of Science ®Google Scholar
• LevkovitzYMendlovichSRiwkesSA double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophreniaJ Clin Psychiatry201071213814919895780
   PubMed Web of Science ®Google Scholar
• ChaudhryIBHallakJHusainNMinocycline benefits negative symptoms in early schizophrenia: a randomized double-blind placebo-controlled clinical trial in patients on standard treatmentJ Psychopharmacol20122691185119322526685
   PubMed Web of Science ®Google Scholar
• MullerNMyintAMSchwarzMJInflammation in schizophreniaAdv Protein Chem Struct Biol201288496822814706
   PubMed Web of Science ®Google Scholar
• AshdownHDumontYNgMPooleSBoksaPLuheshiGNThe role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophreniaMol Psychiatry2006111475516189509
   PubMed Web of Science ®Google Scholar
• ShenQLiZQSunYThe role of pro-inflammatory factors in mediating the effects on the fetus of prenatal undernutrition: implications for schizophreniaSchizophr Res2008991–3485518065207
   PubMed Web of Science ®Google Scholar
• MeyerUDevelopmental neuroinflammation and schizophreniaProg Neuropsychopharmacol Biol Psychiatry201342203422122877
   PubMed Web of Science ®Google Scholar
• ArionDUngerTLewisDALevittPMirnicsKMolecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophreniaBiol Psychiatry200762771172117568569
   PubMed Web of Science ®Google Scholar
• NarayanSTangBHeadSRMolecular profiles of schizophrenia in the CNS at different stages of illnessBrain Res2008123923524818778695
   PubMed Web of Science ®Google Scholar
• BessisABechadeCBernardDRoumierAMicroglial control of neuronal death and synaptic propertiesGlia200755323323817106878
   PubMed Web of Science ®Google Scholar
• SteinerJBogertsBSarnyaiZBridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrityWorld J Biol Psychiatry201213748249221707463
   PubMed Web of Science ®Google Scholar
• AlliotFGodinIPessacBMicroglia derive from progenitors, originating from the yolk sac, and which proliferate in the brainBrain Res Dev Brain Res19991172145152
   Google Scholar
• Pont-LezicaLBechadeCBelarif-CantautYPascualOBessisAPhysiological roles of microglia during developmentJ Neurochem2011119590190821951310
   PubMed Web of Science ®Google Scholar
• SchlegelmilchTHenkeKPeriFMicroglia in the developing brain: from immunity to behaviourCurr Opin Neurobiol201121151020817438
   PubMed Web of Science ®Google Scholar
• TremblayMEMajewskaAKA role for microglia in synaptic plasticity?Commun Integr Biol20114222022221655446
   PubMedGoogle Scholar
• TremblayMEStevensBSierraAWakeHBessisANimmerjahnAThe role of microglia in the healthy brainJ Neurosci20113145160641606922072657
   PubMed Web of Science ®Google Scholar
• NurunBNTanakaTKaminoKToll-like receptor 3 mediated hyperphosphorylation of tau in human SH-SY5Y neuroblastoma cellsPsychiatry Clin Neurosci200660Suppl 1S27S33
   Google Scholar
• BlockMLHongJSMicroglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanismProg Neurobiol2005762779816081203
   PubMed Web of Science ®Google Scholar
• LiebermanJAIs schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspectiveBiol Psychiatry199946672973910494440
   PubMed Web of Science ®Google Scholar
• Perez-NeriIRamirez-BermudezJMontesSRiosCPossible mechanisms of neurodegeneration in schizophreniaNeurochem Res200631101279129417006758
   PubMed Web of Science ®Google Scholar
• NakkiRKoistinahoJSharpFRSagarSMCerebellar toxicity of phencyclidineJ Neurosci1995153 Pt 2209721087891155
   PubMed Web of Science ®Google Scholar
• NakkiRNickolenkoJChangJSagarSMSharpFRHaloperidol prevents ketamine- and phencyclidine-induced HSP70 protein expression but not microglial activationExp Neurol199613722342418635538
   PubMed Web of Science ®Google Scholar
• SteinerJMawrinCZiegelerADistribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralizationActa Neuropathol2006112330531616783554
   PubMed Web of Science ®Google Scholar
• SteinerJBielauHBrischRImmunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicideJ Psychiatr Res200842215115717174336
   PubMed Web of Science ®Google Scholar
• BayerTABusleiRHavasLFalkaiPEvidence for activation of microglia in patients with psychiatric illnessesNeurosci Lett1999271212612810477118
   PubMed Web of Science ®Google Scholar
• RadewiczKGareyLJGentlemanSMReynoldsRIncrease in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenicsJ Neuropathol Exp Neurol200059213715010749103
   PubMed Web of Science ®Google Scholar
• Wierzba-BobrowiczTLewandowskaELechowiczWStepieńTPasennikEQuantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenicsFolia Neuropathol2005432818916012909
   PubMed Web of Science ®Google Scholar
• Van BerckelBNBossongMGBoellaardRMicroglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography studyBiol Psychiatry200864982082218534557
   PubMed Web of Science ®Google Scholar
• DoorduinJde VriesEFWillemsenATde GrootJCDierckxRAKleinHCNeuroinflammation in schizophrenia-related psychosis: a PET studyJ Nucl Med200950111801180719837763
   PubMed Web of Science ®Google Scholar
• TakahashiNSakuraiTRoles of glial cells in schizophrenia: possible targets for therapeutic approachesNeurobiol Dis201353496023146995
   PubMed Web of Science ®Google Scholar
• FrickLRWilliamsKPittengerCMicroglial dysregulation in psychiatric diseaseClin Dev Immunol2013201360865423690824
   PubMedGoogle Scholar
• MonjeMLTodaHPalmerTDInflammatory blockade restores adult hippocampal neurogenesisScience200330256511760176514615545
   PubMed Web of Science ®Google Scholar
• EkdahlCTClaasenJHBondeSKokaiaZLindvallOInflammation is detrimental for neurogenesis in adult brainProc Natl Acad Sci U S A200310023136321363714581618
   PubMed Web of Science ®Google Scholar
• CacciEClaasenJHKokaiaZMicroglia-derived tumor necrosis factor-alpha exaggerates death of newborn hippocampal progenitor cells in vitroJ Neurosci Res200580678979715884015
   PubMed Web of Science ®Google Scholar
• IosifREEkdahlCTAhleniusHTumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesisJ Neurosci200626389703971216988041
   PubMed Web of Science ®Google Scholar
• KanekoNKudoKMabuchiTSuppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrusNeuropsychopharmacology200631122619262616823390
   PubMed Web of Science ®Google Scholar
• MullerNKrauseDDehningSCelecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatmentSchizophr Res20101211–311812420570110
   PubMed Web of Science ®Google Scholar
• MullerNRiedelMScheppachCBeneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophreniaAm J Psychiatry200215961029103412042193
   PubMed Web of Science ®Google Scholar
• YrjänheikkiJKeinänenRPellikkaMHökfeltTKoistinahoJTetracyclines inhibit microglial activation and are neuroprotective in global brain ischemiaProc Natl Acad Sci U S A1998952615769157749861045
   PubMed Web of Science ®Google Scholar
• YrjänheikkiJTikkaTKeinänenRGoldsteinsGChanPHKoistinahoJA tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic windowProc Natl Acad Sci U S A19999623134961350010557349
   PubMed Web of Science ®Google Scholar
• DommeguessMAPlaisantFVermeyCGressensPEarly microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotectionNeuroscience2003121361962814568022
   PubMed Web of Science ®Google Scholar
• TikkaTFiebichBLGoldsteinsGKeinanenRKoistinahoJMinocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microgliaJ Neurosci20012182580258811306611
   PubMed Web of Science ®Google Scholar
• ArvinKLHanBHDuYLinSZPaulSMHoltzmanDMMinocycline markedly protects the neonatal brain against hypoxic-ischemic injuryAnn Neurol2002521546112112047
   PubMed Web of Science ®Google Scholar
• ChenMOnaVOLiMMinocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington diseaseNat Med20006779780110888929
   PubMed Web of Science ®Google Scholar
• WuDCJackson-LewisVVilaMBlockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson diseaseJ Neurosci20022251763177111880505
   PubMed Web of Science ®Google Scholar
• HomsiSFedericoFCrociNMinocycline effects on cerebral edema: relations with inflammatory and oxidative stress markers following traumatic brain injury in miceBrain Res2009129112213219631631
   PubMed Web of Science ®Google Scholar
• AhujaMBishnoiMChopraKProtective effect of minocycline, a semi-synthetic second-generation tetracycline against 3-nitropropionic acid (3-NP)-induced neurotoxicityToxicology20082442–311112218164115
   PubMed Web of Science ®Google Scholar
• Garcia-MartinezEMSanz-BlascoSKarachitosAMitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cellsBiochem Pharmacol201079223925019682437
   PubMed Web of Science ®Google Scholar
• DavisKLStewartDGFriedmanJIWhite matter changes in schizophrenia: evidence for myelin-related dysfunctionArch Gen Psychiatry200360544345612742865
   PubMed Web of Science ®Google Scholar
• KumraSAshtariMCervellioneKLWhite matter abnormalities in early-onset schizophrenia: a voxel-based diffusion tensor imaging studyJ Am Acad Child Adolesc Psychiatry200544993494116113622
   PubMed Web of Science ®Google Scholar
• SalisburyDFKurokiNKasaiKShentonMEMcCarleyRWProgressive and interrelated functional and structural evidence of post-onset brain reduction in schizophreniaArch Gen Psychiatry200764552152917485604
   PubMed Web of Science ®Google Scholar
• Hulshoff PolHEKahnRSWhat happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophreniaSchizophr Bull200834235436618283048
   PubMed Web of Science ®Google Scholar
• GlantzLAGilmoreJHLiebermanJAJarskogLFApoptotic mechanisms and the synaptic pathology of schizophreniaSchizophr Res2006811476316226876
   PubMed Web of Science ®Google Scholar
• OlanowCWJennerPBrooksDDopamine agonists and neuroprotection in Parkinson’s diseaseAnn Neurol1998443 Suppl 1S167S1749749590
   PubMed Web of Science ®Google Scholar
• MedinaSMartinezMHernanzAAntioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42Free Radic Res200236111179118412592670
   PubMed Web of Science ®Google Scholar
• BuntinxMMoreelsMVandenabeeleFCytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-gamma and TNF-alpha on apoptosisJ Neurosci Res200476683484515160395
   PubMed Web of Science ®Google Scholar
• ThomasMLeWDMinocycline: neuroprotective mechanisms in Parkinson’s diseaseCurr Pharm Des200410667968614965330
   PubMed Web of Science ®Google Scholar
• AlanoCCKauppinenTMVallsAVSwansonRAMinocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrationsProc Natl Acad Sci U S A2006103259685969016769901
   PubMed Web of Science ®Google Scholar
• BrundulaVRewcastleNBMetzLMBernardCCYongVWTargeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosisBrain.2002125Pt 61297130812023318
   PubMed Web of Science ®Google Scholar
• WangJWeiQWangCYHillWDHessDCDongZMinocycline up-regulates Bcl-2 and protects against cell death in mitochondriaJ Biol Chem200427919199481995415004018
   PubMed Web of Science ®Google Scholar
• CastanaresMVeraYErkkilaKMinocycline up-regulates BCL-2 levels in mitochondria and attenuates male germ cell apoptosisBiochem Biophys Res Commun2005337266366916202388
   PubMed Web of Science ®Google Scholar
• ScarabelliTMStephanouAPasiniEMinocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to SMAC/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLOJ Am Coll Cardiol200443586587414998631
   PubMed Web of Science ®Google Scholar
• ChenMOnaVOLiMMinocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington diseaseNat Med20006779780110888929
   PubMed Web of Science ®Google Scholar
• TengYDChoiHOnarioRCMinocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injuryProc Natl Acad Sci U S A200410193071307614981254
   PubMed Web of Science ®Google Scholar
• YangDLiuXZhangRIncreased apoptosis and different regulation of pro-apoptosis protein bax and antiapoptosis protein bcl-2 in the olfactory bulb of a rat model of depressionNeurosci Lett20115041182221903151
   PubMed Web of Science ®Google Scholar
• KerntMNeubauerASEiblKHMinocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2Clin Ophthalmol2010459160420668721
   PubMedGoogle Scholar
• TangCMHwangCSChenSDYangDINeuroprotective mechanisms of minocycline against sphingomyelinase/ceramide toxicity: roles of Bcl-2 and thioredoxinFree Radic Biol Med201150671072121184825
   PubMed Web of Science ®Google Scholar
• ZhuSStavrovskayaIGDrozdaMMinocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in miceNature20024176884747811986668
   PubMed Web of Science ®Google Scholar
• WangXZhuSDrozdaMMinocycline inhibits caspase- independent and dependent mitochondrial cell death pathways in models of Huntington’s diseaseProc Natl Acad Sci U S A200310018104831048712930891
   PubMed Web of Science ®Google Scholar
• FuksBTalagaPHuartCIn vitro properties of 5-(benzylsulfonyl)-4-bromo-2- methyl- 3(2H)-pyridazinone: a novel permeability transition pore inhibitorEur J Pharmacol20055191–2243016099453
   PubMed Web of Science ®Google Scholar
• LeungAWHalestrapAPRecent progress in elucidating the molecular mechanism of the mitochondrial permeability transition poreBiochim Biophys Acta200817777–894695218407825
   PubMed Web of Science ®Google Scholar
• MorimotoNShimazawaMYamashimaTNagaiHHaraHMinocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damageBrain Res20051044181515862784
   PubMed Web of Science ®Google Scholar
• KrausRLPasiecznyRLariosa-WillinghamKTurnerMSJiangATraugerJWAntioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activityJ Neurochem200594381982716033424
   PubMed Web of Science ®Google Scholar
• WiedholzLMOwensWAHortonREMice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and ‘schizophrenia-related’ behaviorsMol Psychiatry200813663164017684498
   PubMed Web of Science ®Google Scholar
• WoolleyMLWatersKAGartlonJEEvaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the ratPsychopharmacology (Berl)20092021–334335418795266
   PubMed Web of Science ®Google Scholar
• WangJQAroraAYangLPhosphorylation of AMPA receptors: mechanisms and synaptic plasticityMol Neurobiol200532323724916385140
   PubMed Web of Science ®Google Scholar
• DuYMaZLinSMinocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s diseaseProc Natl Acad Sci U S A20019825146691467411724929
   PubMed Web of Science ®Google Scholar
• WassermanJKSchlichterLCNeuron death and inflammation in a rat model of intracerebral hemorrhage: effects of delayed minocycline treatmentBrain Res20071136120821817223087
   PubMed Web of Science ®Google Scholar
• ZhangLKitaichiKFujimotoYProtective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamineProg Neuropsychopharmacol Biol Psychiatry20063081381139316839653
   PubMed Web of Science ®Google Scholar
• LevkovitzYLeviUBrawYCohenHMinocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophreniaBrain Res2007115415416217488642
   PubMed Web of Science ®Google Scholar
• MonteASde SouzaGCMcIntyreRSPrevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: possible involvement of antioxidant and nitrergic pathwaysJ Psychopharmacol201327111032104324045882
   PubMed Web of Science ®Google Scholar
• HashimotoKTsukadaHNishiyamaSFukumotoDKakiuchiTIyoMProtective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a positron emission tomography study in conscious monkeysBiol Psychiatry200761557758116712806
   PubMed Web of Science ®Google Scholar
• ZhangLShirayamaYIyoMHashimotoKMinocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpineNeuropsychopharmacology20073292004201017228338
   PubMed Web of Science ®Google Scholar
• FujitaYIshimaTKunitachiSPhencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocyclineProg Neuropsychopharmacol Biol Psychiatry200832233633917884273
   PubMed Web of Science ®Google Scholar
• MizoguchiHTakumaKFukakusaAImprovement by minocycline of methamphetamine-induced impairment of recognition memory in micePsychopharmacology (Berl)2008196223324117909751
   PubMed Web of Science ®Google Scholar
• MiyaokaTYasukawaRYasudaHHayashidaMInagakiTHoriguchiJPossible antipsychotic effects of minocycline in patients with schizophreniaProg Neuropsychopharmacol Biol Psychiatry200731130430717030375
   PubMed Web of Science ®Google Scholar
• ChavesCde MarqueCRWichert-AnaLFunctional neuroimaging of minocycline’s effect in a patient with schizophreniaProg Neuropsychopharmacol Biol Psychiatry201034355055220138948
   PubMed Web of Science ®Google Scholar
• MiyaokaTYasukawaRYasudaHHayashidaMInagakiTHoriguchiJMinocycline as adjunctive therapy for schizophrenia: an open-label studyClin Neuropharmacol200831528729218836347
   PubMed Web of Science ®Google Scholar
• KellyDLVyasGRichardsonCMAdjunct minocycline to clozapine treated patients with persistent schizophrenia symptomsSchizophr Res20111331–325725821872445
   PubMed Web of Science ®Google Scholar
• JhamnaniKShivakumarVKalmadySRaoNPVenkatasubramanianGSuccessful use of add-on minocycline for treatment of persistent negative symptoms in schizophreniaJ Neuropsychiatry Clin Neurosci2013251E06E0723487204
   PubMed Web of Science ®Google Scholar
• LevkovitzYMendlovichSRiwkesSA double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophreniaJ Clin Psychiatry201071213814919895780
   PubMed Web of Science ®Google Scholar
• ChaudhryIBHallakJHusainNMinocycline benefits negative symptoms in early schizophrenia: a randomized double-blind placebo-controlled clinical trial in patients on standard treatmentJ Psychopharmacol20122691185119322526685
   PubMed Web of Science ®Google Scholar
• SofuogluMMooneyMKostenTWatersAHashimotoKMinocycline attenuates subjective rewarding effects of dextroamphetamine in humansPsychopharmacology (Berl)20112131616820838775
   PubMed Web of Science ®Google Scholar